Mia's Feed
Medical News & Research

New Study Confirms Safety and Effectiveness of Monoclonal Antibody Therapy in Rabies Prevention

New Study Confirms Safety and Effectiveness of Monoclonal Antibody Therapy in Rabies Prevention

Share this article

A recent clinical study confirms the safety and effectiveness of Rabishield, a monoclonal antibody treatment, in preventing rabies after animal bites, offering hope for better global rabies control.

2 min read

Rabies remains one of the deadliest infectious diseases worldwide, but recent advances in treatment have shown promise in preventing this fatal illness after animal bites. A comprehensive post-licensure clinical study published in The Lancet highlights the safety and efficacy of Rabishield, a monoclonal antibody therapy developed by UMass Chan Medical School in collaboration with the Serum Institute of India. This innovative treatment offers a compelling alternative to traditional rabies post-exposure prophylaxis options.

Rabishield, launched globally in 2017, especially aimed to bridge gaps in rabies prevention, notably in countries like India where the disease causes approximately 20,000 deaths annually. In the study involving over 4,000 high-risk patients in India, participants received Rabishield combined with rabies vaccines or the conventional equine rabies immunoglobulin plus vaccine. Both groups developed strong immune responses, but Rabishield was better tolerated, with fewer significant side effects, and crucially, no cases of rabies were reported during a one-year follow-up.

This research underscores Rabishield's vital role in expanding access to life-saving rabies treatment, particularly in regions where rabies remains a significant public health challenge. The findings contribute to global efforts to reduce rabies mortality and demonstrate the potential of monoclonal antibody therapies in infectious disease management.

For more details, see the full study: Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients in The Lancet, 2025. Source: https://medicalxpress.com/news/2025-09-highlights-monoclonal-antibody-therapy-safe.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Reducing Tackle Height in Women's Rugby Leads to Safer Play, Study Finds

A groundbreaking study demonstrates that lowering tackle height in women's rugby significantly reduces head contacts and enhances player safety, paving the way for better injury prevention policies.

New Insight into Brain Circuits Offering Potential for Improved Pain Relief

Scientists have uncovered a neural pathway in the brain that controls pain suppression during fear, offering promising avenues for better pain management therapies.

Many Niece and Nephew Dementia Caregivers Unprepared When They Take On Role, Study Reveals

Virginia Tech's study reveals that most nieces and nephews caring for relatives with dementia step into their roles unexpectedly, often driven by love and family bonds, facing significant responsibilities without prior preparation.

Promising Results of Zidesamtinib in Treating ROS1-Positive NSCLC Patients Post-TKI Therapy

Zidesamtinib shows promising durable responses in ROS1-positive NSCLC patients, including those with brain metastases and prior TKI treatment, demonstrating potential as a targeted therapy option.